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Introduction
Renal excretion is a major elimination pathway for many drugs and drug metabolites.
Besides glomerular filtration, circulating drugs are actively secreted by carrier-mediated pathways in the renal proximal tubules. In humans, secretion of organic cation (OC) drugs is primarily accomplished by basolateral uptake via the electrogenic organic cation transporter 2 (hOCT2) followed by apical efflux via the proton/OC exchangers multidrug and toxin extrusion proteins 1 and 2-K (hMATE1 and 2-K) (Li et al., 2006; Giacomini, 2010; Morrissey et al., 2012; Motohashi and Inui, 2013) . Anionic drug molecules, on the other hand, are generally first transported into tubular cells by the basolateral organic anion transporters 1 and 3 (hOAT1 and 3) and then effluxed into the lumen by apical transporters such as the multidrug resistanceassociated proteins 2 and 4 (Li et al., 2006; Giacomini, 2010; Morrissey et al., 2012) . These kidney transporters are important pharmacokinetic and pharmacodynamic determinants for a wide array of clinically used drugs (Giacomini, 2010; Morrissey et al., 2012) . Furthermore, an imbalance between transporter-mediated uptake and efflux may result in drug accumulation in proximal tubule cells, leading to drug-induced nephrotoxicity and kidney injury (Li et al., 2006; Morrissey et al., 2012) .
Numerous clinically significant DDIs in the kidney are attributed to the inhibition of renal organic cation or anion secretion systems (Masereeuw and Russel, 2001; Li et al., 2006; Morrissey et al., 2012) . Historically, cimetidine has been used as the classic inhibitor of the OC system whereas probenecid is the prototypical inhibitor of the anion system (Masereeuw and Russel, 2001; Li et al., 2006; Morrissey et al., 2012) . Renal transporter-mediated DDIs are of significant clinical concerns as they can adversely impact drug disposition, efficacy, and toxicity.
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6 Drug Administration (FDA) and the International Transporter Consortium (ITC) have published a series of recommendations to guide industry in the assessment of drug interaction potentials of new molecular entities (NMEs) towards clinically important transporters including hOCT2, hOAT1/3, and hMATE1/2-K (Giacomini, 2010; Zhang et al., 2011; FDA, 2012; Brouwer et al., 2013; Hillgren et al., 2013) . In general, if an NME is an in vitro inhibitor for these transporters and its unbound maximal plasma concentration (C max ) is greater than one-tenth of its half maximal inhibitory concentration (IC 50 ), further in vivo DDI assessment is recommended (Giacomini, 2010; FDA, 2012) . A key parameter in the prediction of DDI risk is the IC 50 (or the inhibition constant K i ) of the NME, which is typically determined in transporter-expressing cell lines using a recommended probe substrate (Brouwer et al., 2013) . Several in vitro substrates, including metformin and 1-methyl-4-phenylpyridinium (MPP+), have been recommended as the probe substrates in preclinical DDI assessment with hOCT2 and hMATEs (FDA, 2012; Hillgren et al., 2013) . This approach assumes that the K i or IC 50 value of an NME determined with a probe substrate is a constant and can be extrapolated to predict the in vivo interaction of the NME with clinically used drugs. However, several drug-metabolizing enzymes including CYP3A4 and 2D6 are known to exhibit substrate-dependent inhibition, where the K i or IC 50 value of an inhibitor can vary considerably depending on the probe substrate used (Kenworthy et al., 1999; VandenBrink et al., 2012) . To mitigate the risk of false-negative prediction, the use of two or more probe substrates or a sensitive drug substrate for these enzymes has been suggested (Yuan et al., 2002; FDA, 2012) .
Emerging evidence suggests substrate-dependent inhibition can also occur with drug transporters (Belzer et al., 2013; Martinez-Guerrero and Wright, 2013; Izumi et al., 2015) . Using metformin and several experimental compounds as the probe substrates, Wright and coworkers J P E T # 2 3 6 1 5 8 7
showed that inhibition of hOCT2 and hMATE1 is substrate-dependent (Belzer et al., 2013; Martinez-Guerrero and Wright, 2013) . However, except for metformin, all other substrates used in these studies were experimental compounds not used in humans, making it difficult to infer the clinical impact of substrate-dependent inhibition on DDI prediction. Moreover, the influence of substrate-dependent inhibition on overall tubular secretion has never been studied. Its impact on intracellular drug accumulation, which is an important predictor for drug-induced nephrotoxicity, is also unknown. In this study, we investigated the influence of probe substrate choice on predicting transporter-mediated DDIs using metformin and a newly identified drug substrate of hOCT2 and hMATEs, atenolol (Yin et al., 2015) . The overall impact of substratedependent inhibition on tubular secretion and intracellular accumulation was also investigated using a double-transfected cell culture model of renal OC secretion. All other chemicals were purchased from Sigma-Aldrich (St. Louis, MO) and were of analytical grade.
Cell lines and cell culture. Control (pcDNA5-transfected) and Flp-In HEK293 cell lines stably expressing hOCT2, hMATE1 and hMATE2-K were previously established and maintained in Dulbecco's modified Eagle's medium (Duan et al., 2015; Yin et al., 2015) . Transporterexpressing cells generally showed much higher (~ 10-to 30-fold) transport activities than control HEK293 cells for a probe substrate (e.g. metformin or MPP+) (Yin et al., 2015) . Both transporter-expressing and control HEK293 cells were maintained in Dulbecco's modified Eagle's medium (high glucose) supplemented with 10% FBS, 2 mM L-glutamine, 100 U/ml penicillin, 100 μ g/ml streptomycin, and 150 μ g/ml hygromycin B. Vectors (pcDNA3.1+ and pcDNA3.1/Hygro(+)) and hOCT2/hMATE1 double-transfected MDCK cell lines were previously established in our laboratory (Yin et al., 2015) . MDCK cells were maintained in minimum essential medium supplemented with 10% FBS, 500 μ g/ml G418, and 200 μ g/ml hygromycin B. All cell lines were cultured in a humidified incubator at 37 °C with 5% CO 2 .
Uptake and inhibition assays in HEK293 cells. In vitro transport and inhibition studies were performed as previously described (Duan and Wang, 2010; Yin et al., 2015) . Briefly, transporter-expressing and control HEK293 cells were seeded in poly-D-lysine-coated plates and allowed to grow for 2 to 3 days to reach 80-90% confluence. Growth medium was then aspirated, This article has not been copyedited and formatted. The final version may differ from this version. of -5.5 and -2.0, respectively) with low non-specific binding to cells and cell culture plates. The 2 min incubation time was chosen as our previous studies showed that it is within the initial rate period of atenolol and metformin uptake for all three transporters (Yin et al., 2015) . hMATE uptake studies were performed in KRH buffer with pH adjusted to 8.0 to maintain an outwardly directed proton gradient to drive cellular uptake of the OC substrate because hMATEs function as proton/organic cation exchangers (Otsuka et al., 2005) . For hOCT2, uptake was performed at pH 7.4. Uptake was terminated by washing cells three times with ice-cold KRH buffer. Cells were then solubilized with 0.5 ml of 1 M NaOH at 37 °C and neutralized with an equal volume of 1 M HCl. The radioactivity of cell lysates was quantified by a liquid scintillation counter (PerkinElmer, Tri-Carb B3110TR, Waltham, MA) and the protein content was determined by a BCA Protein Assay Kit (Pierce Chemical, Rockford, IL). Cellular uptake was normalized by the total protein content in each well. In all studies, uptake in vector-transfected cells was performed at each data point and used to control for nonspecific substrate uptake and binding. Transporterspecific uptake was calculated by subtracting background uptake in vector-transfected cells from the uptake measured in transporter-expressing cells. Each data measurement was performed in triplicates in three different wells. Each experiment was repeated at least 2 times.
Transwell studies in MDCK-hOCT2/hMATE1 cells. 
Ω
•cm 2 were accepted. In addition, proper formation of tight junctions was also verified by measurement of transepithelial flux of mannitol as described previously (Yin et al., 2015) . After removing cell culture medium from both sides of the inserts, cells were pre-incubated at 37 °C for 10 min in KRH buffer with the pH in the apical and basal chambers maintained at 6.0 and 7.4 respectively. Transwell transport studies were then initiated after aspirating the pre-incubation buffer from both apical and basal chambers.
For apical-to-basal (A-to-B) transport, 2 ml of KRH buffer (pH 7.4) was first added to the basal chamber, and the transport was initiated by adding 0.8 ml of KRH buffer (pH 6.0) containing a radiolabeled substrate to the apical chamber. Similarly, for basal-to-apical (B-to-A) transport, 0.8 ml of KRH buffer (pH 6.0) was first added to the apical chamber and 2 ml of KRH buffer (pH 7.4) containing a radiolabeled substrate was added to the basal chamber. To measure timedependent transcellular transport, an aliquot of the incubation medium (100 μ l from the basal chamber, 50 μ l from the apical chamber) in the receiving chamber was periodically collected and replaced with an equal volume of fresh buffer. For inhibition studies, cimetidine was applied to the basal, apical or both chambers at the start of the transwell study. At the end of the transwell experiment, inserts were rinsed three times with ice-cold KRH buffer and cells were lysed with 1 M NaOH and then neutralized with 1 M HCl. Intracellular accumulation of the radiolabeled substrate was quantified by liquid scintillation counting and normalized to total protein content , where "V" is the rate of uptake in the presence of inhibitor, "Bottom" is the residual non-inhibitable baseline value, "Top" is the rate of uptake in the absence of inhibitor, "I" is the inhibitor concentration, and "nH" is the Hill coefficient. For transport experiments, the apparent permeability (P app ) of compounds across cell monolayers was calculated as P app = (dQ/dt) / (A*C 0 ), where Q is the amount of compound transported over time t, A is the insert membrane surface area, and C 0 is the initial compound concentration in the donor chamber. Statistical significance was determined using unpaired Student's t test. A P value less than 0.05 was considered statistically significant.
Results
Inhibition of hOCT2 by classic inhibitors is highly dependent on substrate. To determine if cimetidine, the classic inhibitor of renal OC secretion, exhibits substrate-dependent inhibition of hOCT2 and hMATE1/2-K, inhibition studies were conducted using two drug substrates metformin and atenolol. Metformin is a widely used antidiabetic drug and a well-established probe substrate for hOCT2 and hMATE1/2-K while atenolol is a major antihypertensive that was recently identified as an excellent substrate for these transporters (Yin et al., 2015) . Two additional known drug inhibitors of these transporters, pyrimethamine (Kusuhara et al., 2011) and carvedilol (Zolk et al., 2009; Wittwer et al., 2013) , were also tested. Inhibition assays of the two substrates were conducted side-by-side in control and transporter-expressing HEK293 cells and the IC 50 values were determined at a substrate concentration much lower than their K m values (see Supplemental Table 1 ). For hOCT2, substantial substrate-dependent inhibition was observed for all three tested inhibitors ( Figure 1 , Table 1 ). Cimetidine and pyrimethamine were approximately 10-fold more potent toward hOCT2 when atenolol is used as the substrate.
Carvedilol also showed 6-fold higher potency for hOCT2 when atenolol is used. In contrast, substrate-dependent inhibition was much less pronounced for hMATE1 and 2-K ( Figure 1 , Table   1 ). Not all inhibitors showed substrate-dependent inhibition of hMATE transporters. Those that showed dependency had much smaller differences in IC 50 (< 5 fold) as compared to hOCT2.
Interestingly, atenolol is a more sensitive substrate to detect hOCT2 inhibition whereas metformin appears to be a more sensitive substrate for hMATE1 and 2-K inhibition.
To examine the inhibition mechanisms of cimetidine towards hOCT2 and hMATE1/2-K, concentration-dependent uptake of atenolol or metformin was performed in the presence of
different concentrations of cimetidine (0, IC 50 , and 5xIC 50 ). The complete kinetic data along with Lineweaver-Burk plots are also shown (Supplemental Figures 1 and 2) . A close-up view of the double reciprocal plots at the lower x and y range (Figure 2 ) indicate that cimetidine acted as a mixed-type inhibitor of hOCT2 for atenolol but became a competitive inhibitor when metformin was used. Cimetidine acted as a mixed-type inhibitor for both hMATE1 and 2-K regardless of the substrate used.
Substrate-dependent inhibition results in different prediction of DDI potential for hOCT2.
According to the latest FDA draft guidance for hOCT2-mediated DDI studies, an in vivo DDI study is recommended for a compound if its unbound C max /IC 50 is greater than 0.1 (FDA, 2012) .
Cimetidine is 20% protein bound in the plasma and the reported unbound C max after a typical 400 mg oral dose is around 8 µM (Somogyi et al., 1980; Somogyi et al., 1989) . Our study showed that the IC 50 values of cimetidine towards hOCT2 differ by 10-fold when different drug substrates are used.
To examine if substrate-dependent inhibition leads to different recommendations for in vivo DDI assessment, the unbound C max /IC 50 values of cimetidine were calculated for atenolol and metformin. In addition, the reported cimetidine IC 50 towards MPP+ (Ito et al., 2012) , a recommended in vitro probe for hOCT2, was also used for prediction. Very different recommendations for cimetidine in vivo DDI study were obtained for hOCT2 with a "Yes" for atenolol, a "No" for MPP + , and a borderline value for metformin (Table 2 ). These data demonstrated that substrate-dependent inhibition can significantly impact the outcome of DDI prediction for hOCT2. Compared to hOCT2, cimetidine is generally a more potent inhibitor for hMATE1/2-K and showed less pronounced substrate-dependent inhibition (Table 1) inhibition data (Table 1 and Figure 1 ) showed that cimetidine is an equally potent inhibitor of hOCT2 and hMATE1 when atenolol is the substrate but becomes a hMATE1-selective inhibitor if metformin is used. These data suggest that while cimetidine reduces tubular secretion for hOCT2/hMATE substrates, its effect on intracellular drug accumulation may be substratedependent. Indeed, when the apparent permeability was calculated, cimetidine applied to the basal or both chambers showed a clear inhibitory effect on B-to-A permeability of atenolol and metformin ( Figure 4A , B). When the intracellular drug accumulation was measured in the absence of cimetidine at the end of the transwell study, intracellular drug accumulation is significantly higher in hOCT2/hMATE1 cells than in vector-transfected cells ( Figure 4C and D).
Interestingly, cimetidine, applied to either basal or both chambers, had no effect on intracellular atenolol accumulation ( Figure 4C ), which is consistent with its similar inhibition potencies for hOCT2 and hMATE1 when atenolol is used as the substrate (Table 1 ). In contrast, cimetidine dose-dependently increased the intracellular accumulation of metformin when applied to basal or both chambers ( Figure 4D ), suggesting a predominant inhibition of the apical hMATE1 when metformin is used as the substrate (Table 1) . These data, obtained from a cell culture model of renal OC secretion, suggest that inhibitors of tubular secretion can impact intracellular drug accumulation in a substrate-dependent manner and the major substrate-inhibitor interacting site for a given inhibitor can shift between the apical and basolateral OC transporters depending on the substrate used. 
Discussion
In this study, we investigated the impact of substrate-dependent inhibition on transportermediated drug interaction and accumulation by focusing on the hOCT2/hMATE-mediated renal secretion pathway. Several novel findings were obtained. First, our data showed that the choice of a probe substrate has a larger impact on hOCT2 than hMATEs in their interactions with inhibitors. Secondly, atenolol is a more sensitive substrate than metformin for evaluating hOCT2-inhibitor interactions in vitro. Further, substrate-dependent inhibition can complicate in vitro-to-in vivo DDI prediction for hOCT2 and lead to different recommendations for in vivo DDI studies. Thirdly, we showed that while cimetidine inevitably reduced hOCT2/hMATE1-mediated transepithelial flux of a drug substrate, its impact on intracellular drug accumulation, thus toxicity, can be unpredictable due to substrate-dependent shifting of the major interaction site between apical and basolateral transporters. Lastly, our data provided the first evidence that cimetidine concentrations in the basolateral side (i.e. blood) may be more relevant than those in the apical side (i.e. filtrate) to estimate its inhibitory effects on renal hOCT2 and hMATE1/2-K transporters.
In our study, metformin and atenolol were used as the substrates to probe potential substrate-dependent inhibition of renal OC transporters. Our data showed that cimetidine, as well as pyrimethamine and carvedilol, are much more potent inhibitors of hOCT2 when atenolol is used as the substrate (Figure 1 , Table 1 ). In contrast, substrate-dependent inhibition was less pronounced for hMATE1 and 2-K ( Figure 1 , Table 1 ). These data suggest that the choice of a probe substrate can greatly influence the inhibition potency of a potential inhibitor (e.g. an NME), especially for hOCT2, leading to very different recommendations for in vivo DDI studies as exemplified in Table 2 . Accordingly, it may be necessary to evaluate two or more probe
substrates in in vitro studies for drug transporters that display substantial substrate-dependent inhibition. To mitigate the risk of false-negative predictions, a sensitive substrate, which consistently produces lower IC 50 or K i values for a range of known inhibitors, should be included.
Lastly, direct in vitro DDI analysis should be performed using a commonly co-medicated drug as the substrate if frequent co-administration is anticipated (e.g. two anti-hypertensive drugs used simultaneously).
In the current ITC and FDA recommendations, MPP+ and metformin are suggested as the probe substrates for assessing the inhibition potential of a NME towards hOCT2 (Giacomini, 2010; FDA, 2012; Hillgren et al., 2013) . Belzer et al. previously reported that structurally diverse hOCT2 inhibitors were generally more effective (up to 9-10 fold) for inhibition of metformin than for MPP+ (Belzer et al., 2013) , suggesting that metformin is a more sensitive hOCT2 substrate than MPP+. Our data revealed that atenolol is an even more sensitive (up to 10 fold) hOCT2 substrate than metformin. Like metformin, atenolol is minimally metabolized in vivo and exclusively eliminated unchanged by the kidney. With a LogD 7.4 of -2.0, atenolol is highly hydrophilic with minimal passive membrane diffusion and non-specific binding. We recently showed that atenolol is an excellent hOCT2 substrate and also has a higher apparent affinity for hOCT2 than metformin (Supplemental Table 1 ) (Yin et al., 2015) . These characteristics bestow atenolol as a clinically relevant, more sensitive probe substrate than metformin for assessing hOCT2 inhibitors in vitro. However, available DDI data did not suggest a positive in vivo interaction for atenolol and cimetidine (Houtzagers et al., 1982; Kirch et al., 1982; Mutschler et al., 1984) . The total renal clearance of atenolol (~168 mL/min) is only 1.4
fold of its glomerular filtration clearance (~120 mL/min), suggesting that active tubular secretion only contributes to a minor (~30%) part of atenolol total clearance. This makes it difficult to
observe clinically significant pharmacokinetic interactions of atenolol in vivo. In contrast, metformin has a total renal clearance of ~454 mL/min with a much larger (75%) contribution from tubular secretion. Thus, to assess hOCT2-mediated DDIs in vivo, metformin may be more revealing than atenolol to detect systemic exposure or renal clearance changes caused by inhibition of tubular secretion.
Drug-induced nephrotoxicity is a major concern during drug discovery and development revealed that cimetidine is a hMATE-selective inhibitor when metformin is the substrate but acts as an equally potent inhibitor for hOCT2 and hMATE1 when atenolol is the substrate (Table 1 ).
These data suggest that depending on the substrate (i.e. the victim drug), the site of cimetidine interaction is changeable between the apical and basolateral OC transporters. Consequently, the effect of an inhibitor on intracellular accumulation is also substrate-dependent, leading to either a nephron-toxic or a nephron-protective effect. This concept, supported by our transwell studies on atenolol and metformin (Figures 3 and 4) , is illustrated in Figure 6 . Our studies demonstrated that the effect of a transport inhibitor on intracellular drug accumulation is dynamic and substrate-dependent; and information obtained with one inhibitor-substrate pair may not be extrapolated to other drug combinations containing the same inhibitor.
To predict transporter-mediated renal DDIs, the unbound plasma concentration of the inhibitor is often used (Giacomini, 2010; FDA, 2012 ). An intriguing observation in our study is that although cimetidine inhibited hMATE1-mediated atenolol or metformin uptake in HEK293 cells, it had no inhibitory effect on hMATE1-mediated substrate efflux in transwell studies in MDCK cells when applied apically (Figures 3 and 4) . These seemingly paradoxical observations may be explained by the unique transport mechanism of the MATE transporters, which function as proton/OC antiporters and simultaneously transport proton in the opposite direction of OC substrate (Otsuka et al., 2005) . For these transporters, proton binding always occurs on the opposite side of OC substrate binding. In the uptake studies in HEK293 cells, an extracellular pH of 8.0 was used to create an outwardly-directed proton gradient to drive cellular uptake of the OC substrate. Proton binds intracellularly while substrate/inhibitor binds from the extracellular side, which allows the measurement of the inhibitory effect of cimetidine in these studies. In contrast, in the transwell studies in MDCK cells, the pH in the basal and apical chambers was
respectively maintained at 7.4 and 6.0 to mimic the physiological environment in the nephron.
The acidic pH in the apical compartment creates an inwardly-directed proton gradient to drive hMATE1-mediated substrate efflux from MDCK cells. Under this condition, proton binds from the outside whereas substrate/inhibitor binds from the inside of the MDCK cells (see Figure 6 ).
The configuration of the hMATE1 transporter may allow the substrate/inhibitor binding site (s) only accessible from the intracellular side. As apically applied cimetidine cannot diffuse into MDCK cells due to its low passive diffusion (LogP = 0.4), the inhibitor may not gain access to the intracellularly orientated binding site under this condition. Thus, apically applied cimetidine lacks an effect on hMATE1 whereas basally applied cimetidine, after being transported into cells by hOCT2, can exert an inhibitory effect on hMATE1. This hypothesis is in agreement with data presented in Figure 5 demonstrating a much higher intracellular accumulation of cimetidine when applied to the basal compartment. Together, our studies suggest that plasma and intracellular concentrations of cimetidine, as compare to its filtrate or urine concentrations, may be more relevant to assess hOCT2/hMATE1-mediated cimetidine-drug interactions in the kidney.
In summary, we demonstrated that the choice of a probe substrate can greatly impact the prediction of hOCT2-mediated renal drug interaction and accumulation. Our findings revealed the complex and dynamic nature of substrate-inhibitor interactions in multispecific drug transporters and highlighted the importance of considering substrate-dependent inhibition in assessing transporter-mediated renal drug interaction, accumulation and toxicity.
This article has not been copyedited and formatted. The final version may differ from this version. Concentration-dependent uptake of atenolol in the absence and presence of cimetidine was measured in both transporter-expressing and vector-transfected (control) HEK293 cells after 2-min incubation at 37 °C (A, C, E). Each data point represents mean ± SD (n = 6). Transporter-specific uptake was obtained by subtracting background uptake in control cells from uptake in transporter-expressing cells. Cimetidine concentration used was based on the corresponding IC 50 values in Table 1 . Concentrations of 1 x IC 50 and 5 x IC 50 were used. Data were fitted with Michaelis-Menten equation using nonlinear regression. Mean values of the kinetic data were transformed into corresponding Lineweaver-Burk plots (B, D, F). Figure 2 . Uptake kinetics of metformin in the absence and presence of cimetidine. Concentration-dependent uptake of metformin in the absence and presence of cimetidine was measured in both transporter-expressing and vector-transfected (control) HEK293 cells after 2 min incubation at 37 °C (A, C, E). Each data point represents mean ± SD (n = 6). Transporter-specific uptake was obtained by subtracting background uptake in control cells from uptake in transporter-expressing cells. Cimetidine concentration used was based on the corresponding IC 50 values in Table 1 . Concentrations of 1 x IC 50 and 5 x IC 50 were used. Data were fitted with Michaelis-Menten equation using nonlinear regression. Mean values of the kinetic data were transformed into the corresponding Lineweaver- Burk plots (B, D, F) .
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